PDT Partners’s Albany Molecular Research Inc AMRI Stock Holding History

PDT Partners’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-133,514	Closed	-$2.9M	–	608
2017 Q2	$2.9M	Buy	133,514 +58,494	+78%	+$1.06M	0.12%	218
2017 Q1	$1.05M	Buy	75,020 +43,420	+137%	+$711K	0.06%	318
2016 Q4	$593K	Sell	31,600 -3,800	-11%	-$64.6K	0.04%	379
2016 Q3	$584K	Hold	35,400	–	–	0.03%	356
2016 Q2	$476K	Hold	35,400	–	–	0.04%	330
2016 Q1	$541K	Hold	35,400	–	–	0.03%	401
2015 Q4	$703K	Buy	+35,400	New	+$673K	0.1%	247
2014 Q1	–	Sell	-36,793	Closed	-$371K	–	1407
2013 Q4	$371K	Sell	36,793 -79,204	-68%	-$957K	0.04%	488
2013 Q3	$1.5M	Sell	115,997 -3,500	-3%	-$43.1K	0.04%	620
2013 Q2	$1.42M	Buy	+119,497	New	+$1.29M	0.03%	682

Other funds holding AMRI

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

PDT Partners's AMRI Position: Q3 2017 in Review

PDT Partners sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 133,514 shares — an estimated $2.9M sold.

PDT Partners first reported a position in AMRI in Q2 2013 and held it in 10 quarters. The position peaked at $2.9M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

PDT Partners reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
PDT Partners sold 133,514 Albany Molecular Research Inc shares in Q3 2017, an estimated $2.9M.
PDT Partners first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 10 quarters.
PDT Partners's Albany Molecular Research Inc position peaked at $2.9M in Q2 2017.
2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on PDT Partners's 13F filing for Q3 2017, filed 14 Nov 2017.